covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Diagnóstico prenatal del retraso de crecimiento intrauterino mediante marcadore...
Información de la revista
Vol. 47. Núm. 5.
Páginas 207-213 (enero 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 47. Núm. 5.
Páginas 207-213 (enero 2004)
Acceso a texto completo
Diagnóstico prenatal del retraso de crecimiento intrauterino mediante marcadores bioquímicos
Biochemical markers in the prenatal diagnosis of intrauterine growth retardation
Visitas
8033
M.D. Gómezaa,
Autor para correspondencia
lolagomez@eresmas.com

Servicio de Obstetricia y Ginecología. Hospital Universitario Sant Joan de Déu. Passeig Sant Joan de Déu, 2. 08950 Esplugues. Barcelona. España
, S. Ferreroa, C. Vallsb, J. Poncea, E. Miróa, M. Borrása, J.M. Laïllaa
a Servicio de Obstetricia y Ginecología. Hospital Universitario Sant Joan de Déu. Esplugues. Barcelona
b Departamento de Hormonas. Laboratorio. Hospital Universitario de Sant Joan de Déu. Esplugues. Barcelona. España
Este artículo ha recibido
Información del artículo
Resumen
Objetivo

Determinar la relación y capacidad diagnóstica de la IGF-I (insulin-like growth factor I), IGFBP-I (insulin-like growth factor binding protein I), leptina, y alfa-fetoproteína (AFP) en líquido amniótico de 14-18 semanas con el desajuste ponderal del feto al nacer.

Sujetos y métodos

Estudio longitudinal y prospectivo. Gestantes con amniocentesis de 14-18 semanas. 86 controles, 18 RCIU (retraso de crecimiento intrauterino) < percentil 10, y 17 RCIU < percentil 5.

Resultados

No se demuestra una correlación significativa entre el RCIU y la IGF-I, la IGFBP-I, y la leptina. La AFP cumple una correlación inversa con la severidad del RCIU; en el RCIU < percentil 10 presentó: sensibilidad (S), 65,7%; especificidad (E), 56,9%; valor predictivo positivo (VPP), 38,3%; valor predictivo negativo (VPN), 80,3%, y una capacidad global del 65,6%. En el RCIU < percentil 5 se obtuvo: S, 76,4%; E, 54,8%; VPP, 21,6%; VPN, 93,4%, y una capacidad global del 70,6%. Conclusión: Los valores elevados de AFP en líquido amniótico de diagnóstico prenatal pueden contribuir a la detección precoz de la población con riesgo de desarrollar un RCIU.

Palabras clave:
Retraso de crecimiento intrauterino
Insulin-like growth factor I
Insulin-like growth factor binding protein I
Leptina
Alfa-fetoproteína
Abstract
Objective

To determine the relationship between intrauterine growth retardation (IUGR) and insulinlike growth factor-1 (IGF-I), IGF binding protein-1 (IGFBP-I), leptin, and alfa-fetoprotein (AFP) levels in amniotic fluid after 14-18 weeks of gestation, and to assess the diagnostic utility of these biochemical markers.

Subjects and methods

We performed a longitudinal, prospective study. Amniocentesis was performed in pregnant women after 14-18 weeks of gestation. The study population consisted of 86 controls, 18 IUGR<10 percentile, and 17 IUGR<5 percentile.

Results

No significant correlation was found between the severity of IUGR and IGF-I, IGFBP-I, or leptin. AFP was inversely correlated with the severity of IUGR; the results for IUGR<10 percentile were: sensitivity: 65.7%, specificity: 56.9%, positive predictive value: 38.3%, negative predictive value: 80.3%, and an overall diagnostic capacity of 65.6%. The results for the IUGR<5 percentile were: sensitivity: 76.4%, specificity: 54.8%, positive predictive value: 21.6%, negative predictive value: 93.4%, and an overall diagnostic capacity of 70.6%.

Conclusion

Elevated values of AFP in amniotic fluid may help in the early detection of populations at risk for IUGR.

Keywords:
Intrauterine growth retardation
Insulin-like growth factor I
Insulin-like growth factor binding protein I
Leptin
Alpha-fetoprotein
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Leger, M. Noel, J.M. Limal, P. Czernichow.
Growth factors and intrauterine growth retardation. I. Serum growth hormone, insulin- like growth factor (IGF)-I, IGF-II, and IGF binding protein 3 levels in normally grown and growth-retarded human fetuses during the second half of gestation.
Pediatr Res, 40 (1996), pp. 94-100
[2.]
A. Wiznitzer, E.A. Reece, C. Homko, B. Furman, M. Mazor, J. Levy.
Insulin-like growth factors, their binding proteins, and fetal macrosomia in offspring of nondiabetic pregnant women.
Am J Perinatol, 15 (1998), pp. 23-28
[3.]
S. Cianfarani, D. Germani, L. Rossi, G. Argiro, S. Boemi, M. Lemon, et al.
IGF-I and IGF-binding protein-1 are related to cortisol in human cord blood.
Eur J Endocrinol, 138 (1998), pp. 524-529
[4.]
R. Holmes, R. Montemagno, J. Jones, M. Preece, C. Rodeck, P. Soothill.
Fetal and maternal plasma insulin-like growth factors and binding proteins in pregnancies with appropriate or retarded fetal growth.
Early Hum Dev, 49 (1997), pp. 7-17
[5.]
D. Klauwer, W.F. Blum, S. Hanitsch, W. Rascher, P.D. Lee, W. Kiess.
IGF-I, IGF-II, free IGF-I and IGFBP-1, -2 and -3 levels in venous cord blood: relationship to birthweight, length and gestational age in healthy newborns.
Acta Paediatr, 86 (1997), pp. 826-833
[6.]
M. Osorio, J. Torres, F. Moya, J. Pezzullo, C. Salafia, R. Baxter, et al.
Insulin-like growth factors (IGFs) and IGF binding proteins -1, -2, and -3 in newborn serum: relationships to fetoplacental growth at term.
Early Hum Dev, 46 (1996), pp. 15-26
[7.]
J. Ponce.
Avaluació dels nivells en líquid amniòtic de la IGF-I i la IGFBP-I en fetus afectats per retard de creixement intrauterí (tesi doctoral).
Universitat Autònoma de Barcelona, (1998),
[8.]
L.D. Nonoshita, N.C. Wathen, B.A. Dsupin, T. Chard, L.C. Giudice.
Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and proteolyzed IGFBP-3 in embryonic cavities in early human pregnancy: their potential relevance to maternalembryonic and fetal interactions.
J Clin Endocrinol Metab, 79 (1994), pp. 1249-1255
[9.]
F.M. Reis, P. Florio, L. Cobellis, S. Luisi, F.M. Severi, C. Bocchi, et al.
Human placenta as a source of neuroendocrine factors.
Biol Neonate, 79 (2001), pp. 150-156
[10.]
C.J. Ashworth, N. Hoggard, L. Thomas, J.G. Mercer, J.M. Wallace, R.G. Lea.
Placental leptin.
Rev Reprod, 5 (2000), pp. 18-24
[11.]
I. Cetin, P.S. Morpurgo, T. Radaelli, E. Taricco, D. Cortelazzi, M. Bellotti, et al.
Fetal plasma leptin concentrations relationship with different intrauterine growth patterns from 19 weeks to term.
Pediatr Res, 48 (2000), pp. 646-651
[12.]
L. Gómez, A. Carrascosa, D. Yeste, N. Potau, S. Rique, P. Ruiz-Cuevas, et al.
Leptin values in placental cord blood of human newborns with normal intrauterine growth after 30-42 weeks of gestation.
Horm Res, 51 (1999), pp. 10-14
[13.]
T. Ertl, S. Funke, I. Sarkany, I. Szabo, W. Rascher, W.F. Blum, et al.
Postnatal changes of leptin levels in full-term and preterm neonates: their relation to intrauterine growth, gender and testosterone.
Biol Neonato, 75 (1999), pp. 167-176
[14.]
T.K. Hytinantti, H.A. Koistinen, K. Teramo, S.L. Karonen, V.A. Koivisto, S. Andersson.
Increased fetal leptin in type I diabetes mellitus pregnancies complicated by chronic hypoxia.
Diabetologia, 43 (2000), pp. 709-713
[15.]
C. Schubring, W. Kiess, P. Englaro, W. Rascher, J. Dotsch, S. Hanitsch, et al.
Levels of leptin in maternal serum, amniotic fluid, and arterial and venous cord blood: relation to neonatal and placental weight.
J Clin Endocrinol Metab, 82 (1997), pp. 1480-1483
[16.]
C. Schubring, W. Kiess, P. Englaro, W. Rascher, W. Blum.
Leptin concentrations in amniotic fluid, venous and arterial cord blood and maternal serum: high leptin synthesis in the fetus and inverse correlation with placental weight.
Eur J Pediatr, 155 (1996), pp. 830
[17.]
B.F. Crandall, L. Robinson, P. Grau.
Risks associated with an elevated maternal serum alpha-fetoprotein level.
Am J Obstet Gynecol, 165 (1991), pp. 94
[18.]
G. Huerta-Enochian, V. Katz, S. Erfurth.
The associaton of abnormal alpha-fetoprotein and adverse pregnancy oitcome: does increased fetal surveillance affect pregnancy outcome?.
Am J Obstet Gynecol, 184 (2001), pp. 1549-1553
[19.]
E. Verspyck, S. Degre, M.F. Hellot, G. Descargues, C. Philippe, G. Labadie, et al.
Amniotic fluid alpha-fetoprotein is not a useful biological maker of pregnancy outcome.
Prenat Diagn, 19 (1999), pp. 1031-1034
[20.]
Y. Ochshorn, M.J. Kupferminc, A. Eldor, I. Wolman, J.B. Lessing, Y. Yaron.
Second trimester materna serum alpha-fetoprotein is elevated in women with adverse pregnancy outcome associated with inherited thrombophilias.
Prenat Diagn, 21 (2001), pp. 658-661
[21.]
E. González Bosquet, M.J. Cerqueira, M. Pérez Quintana, M. Cuerda, L.L. Cabero.
Relación entre el peso de nacimiento y la edad de gestación en una población de recién nacidos del Hospital Materno Infantil del Valle de Hebrón.
Prog Obst Gin, 38 (1995), pp. 162-167
[22.]
B. Chevallier, A. Lagarde, H. Degrelle, J. Belaisch-Allart, P. Giraudet, J.P. Gallet.
Insulin-like growth factor binding protein 1 level in amniotic fluid: correlation with birth weight.
Biol Neonate, 73 (1998), pp. 404-406
[23.]
Y. Ohnishi, C. Yamashiro, T. Yanagihara, T. Hata.
Hepatocite growth factor concentration inthe early second-trimester amniotic fluid does not predict fetal growth at birth.
Hum Reprod, 14 (1999), pp. 2625-2628
[24.]
J. Verhaeghe, W. Coopmans, E. Van Herck, D. Van Schoubroeck, J.A. Deprest, I. Witters.
IGF-I, IGF-II, IGF binding protein 1, and C-peptide in second trimester amniotic fluid are dependent on gestational age but do not predict weight at birth.
Pediatr Res, 46 (1999), pp. 101-108
[25.]
S. Cho, K.K. Durfee, B.A. Keel, L.H. Parks.
Perinatal outcomes in a prospective matched pair study of pregnancy and unexplained elevatedor low AFP screening.
J Perinat Med, 25 (1997), pp. 476-483
[26.]
Y. Yaron, M. Cherry, R.L. Kramer, J.E. O’Brien, M. Hallak, M.P. Johnson, et al.
Second-trimester maternal serummarker screening: maternal serum alpha-protein, beta-humanchorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome.
Am J Obstet Gynecol, 181 (1999), pp. 968-974
Copyright © 2004. Sociedad Española de Ginecología y Obstetricia
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos